Trial Profile
A Phase II Study Comparing Efficacy And Safety Of 5-Day Guadecitabine (SGI-110) Regimen Versus 10-day Guadecitabine (SGI-110) Regimen In Treatment-Naive Acute Myeloid Leukemia (TN-AML) Patients Who Were Not Candidates For Intensive Chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2019
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 12 Dec 2017 Results assessing the Predictors of Response and Survival in AML patients Treated with Guadecitabine (n=206) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 04 Feb 2017 New trial record